Posttranslational modifications of α-tubulin in alzheimer disease

Fan Zhang1,2, Bo Su3, Chunyu Wang1,4

  • 1Department of Pathology, Case Western Reserve University, Cleveland, OH 44121 USA.

Abstract

Insights

Alzheimer disease (AD) brains show altered tubulin modifications, with increased acetylation suggesting a compensatory mechanism to stabilize microtubules despite tau pathology. This research offers insights into AD

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Alzheimer disease (AD) is characterized by tau hyperphosphorylation, leading to microtubule destabilization and cytoskeletal abnormalities.
  • Previous studies noted reduced microtubules in AD neurons, but without concurrent paired helical filaments, suggesting compensatory mechanisms.
  • Microtubule stability and function are influenced by posttranslational modifications of tubulin dimers.

Purpose of the Study:

  • To investigate changes in posttranslational modifications of tubulin in postmortem human brain tissues from AD patients and controls.
  • To analyze the impact of these modifications on microtubule stability in the context of Alzheimer disease.

Main Methods:

  • Utilized immunoblot and immunocytochemistry techniques for detailed analysis of tubulin posttranslational modifications.
  • Examined postmortem human brain tissues from individuals with Alzheimer disease and age-matched controls.

Main Results:

  • Observed decreased levels of alpha-tubulin (α-tubulin) in AD brain tissue.
  • Found proportional reductions in polyglutamylation, tyrosination, and detyrosination of tubulin in AD.
  • Noted an increased proportion of acetylated α-tubulin relative to total α-tubulin in AD brains, with altered tubulin distribution.

Conclusions:

  • The specific alterations in tubulin modifications in AD brains are proposed to be a compensatory response.
  • These modifications may play a role in stabilizing microtubule dynamics despite tau pathology and neurofibrillary tangle formation.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
9.9K